Cancer Clinical Trials Information Platform in Hong Kong
-
This serves merely as an information platform about cancer clinical trials operated by different institutions in Hong Kong. HKACS is not responsible for the contents, availability and operability of the trials listed.
- Respective institutions usually reserve all rights regarding the implementation and execution of their respective clinical trials.
- Patients usually need to satisfy a complex and stringent set of selection criteria before being selected/ included in certain clinical trials. Interested parties should contact respective institutions regarding further details of the trials
*in alphabetical order (Last updated on 03/10/2024)
Institution |
Study Title |
|
HKU |
(VT3996-301)An Open-Label, Multicenter Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and in Combination with Pembrolizumab in Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma |
Click for Details |
CUHK |
(NPC036) An Open-Label, Multicenter Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and in Combination with Pembrolizumab in Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma |
Click for Details |
CUHK |
(NPC037) A phase 2 trial of TAS 102 in recurrent/metastatic nasopharyngeal carcinoma |
Click for Details |
CUHK |
(NPC038) NRG-HN011: A RANDOMIZED PHASE II STUDY OF NIVOLUMAB VERSUS NIVOLUMAB AND BMS-986016 (RELATLIMAB) AS MAINTENANCE TREATMENT AFTER FIRST-LINE TREATMENT WITH PLATINUM-GEMCITABINE-NIVOLUMAB FOR PATIENTS WITH EPSTEIN-BARR VIRUS-ASSOCIATED RECURRENT/METASTATIC NASOPHARYNGEAL CARCINOMA (REMAIN) |
Click for Details |
CUHK |
(TRA016) The Immunological Mechanism of Plasma EBV DNA Clearance during Radiotherapy in Patients with Nasopharyngeal Carcinoma-a pilot study |
Click for Details |
For Enquiry, please contact the respective institute, HKACS is not responsible for the outcomes of the clinical trials.